미국의 자기공명 혈관촬영(MRA) 시장 규모, 점유율, 동향 분석 리포트 : 기술별, 적응증별, 최종 용도별, 부문별 예측(2023-2030년)

U.S. Magnetic Resonance Angiography Market Growth & Trends:

The U.S. magnetic resonance angiography market size is expected to reach USD 2.93 billion by 2030, based on a new report by Grand View Research, Inc., expanding at a CAGR of 2.9% from 2023 to 2030 Rising adoption of artificial intelligence (AI) based imaging techniques is expected to contribute to market growth over the forecast period. AI can assist in the detection of abnormal growths, such as tumors. Automatic detection improves the overall patient experience due to faster reporting.

In U.S., around four in ten adults suffer from at least one chronic disease, accounting for around 45% of the total population. Moreover, growing elderly population has given rise to a higher incidence rate of chronic diseases needing better diagnosis, which is anticipated to drive the demand for diagnostic imaging procedures, including magnetic resonance angiography (MRA), in the country. The presence of extensive private and public funding initiatives in U.S. is likely to contribute to market growth. Medicare covers MRI scans ordered by healthcare providers as part of a medical diagnosis.

Some of the patients experience anxiety due to claustrophobia and avoid MRI machines due to fear. Key players such as Philips, Siemens, and Hitachi have launched open bore designs for patients suffering from fear of enclosed spaces. In addition, these companies are offering devices with an audiovisual experience inside the machine to help patients relax while undergoing the procedures. MRI machines use no radiations while diagnosis, unlike CT machines. Hence, demand for MRI and MRA procedures is expected to grow over the coming years.

U.S. Magnetic Resonance Angiography Market Report Highlights:

• By technique, the non-contrast enhanced magnetic resonance angiography segment dominated the market in 2022 in terms of revenue as it is considered to be a safer alternative for patients who are pregnant or are suffering from kidney disorders
• The contrast enhanced MRA segment is expected to register the fastest CAGR over the forecast period as they offer a detailed image of the blood vessels as compared to the tissues or organs surrounding them
• The abdominal MRAs segment is expected to register a maximum CAGR from 2023 to 2030. Abdominal MRAs assist in the assessment and diagnosis of various vascular abnormalities and are performed for the examination of the lymph nodes, blood vessels, blood flow, and to investigate the cause of swelling or pain
• By end use, the hospitals segment dominated the market in 2022 in terms of revenue on account of increased demand for affordable diagnostic services. The imaging centers segment is expected to register the fastest CAGR from 2023 to 2030.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Technique
  • 1.1.2. Indication
  • 1.1.3. End-use
  • 1.1.4. Regional scope
  • 1.1.5. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Technique outlook
  • 2.2.2. Indication outlook
  • 2.2.3. End-use outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Magnetic Resonance Angiography Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Analysis
  • 3.3.2. Market Restraint Analysis
• 3.4. U.S. Magnetic Resonance Angiography Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's Five Forces
    • 3.4.1.1. Supplier power
    • 3.4.1.2. Buyer power
    • 3.4.1.3. Substitution threat
    • 3.4.1.4. Threat of new entrant
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Technological landscape
    • 3.4.2.3. Economic Landscape

Chapter 4. U.S. Magnetic Resonance Angiography Market: Technique Estimates & Trend Analysis

• 4.1. U.S. Magnetic Resonance Angiography Market: Key Takeaways
• 4.2. U.S. Magnetic Resonance Angiography Market: Technique Movement & Market Share Analysis, 2022 & 2030
• 4.3. Contrast-Enhanced MRA
  • 4.3.1. Contrast-Enhanced MRA market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.4. Non-contrast Enhanced MRA
  • 4.4.1. Non-contrast Enhanced MRA market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. U.S. Magnetic Resonance Angiography Market: Indication Estimates & Trend Analysis

• 5.1. U.S. Magnetic Resonance Angiography Market: Key Takeaways
• 5.2. U.S. Magnetic Resonance Angiography Market: Indication Movement & Market Share Analysis, 2022 & 2030
• 5.3. Abdomen
  • 5.3.1. Abdomen market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.4. Lower Extremities
  • 5.4.1. Lower extremities market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.5. Others
  • 5.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. U.S. Magnetic Resonance Angiography Market: End-use Estimates & Trend Analysis

• 6.1. U.S. Magnetic Resonance Angiography Market: Key Takeaways
• 6.2. U.S. Magnetic Resonance Angiography Market: End-use Movement & Market Share Analysis, 2022 & 2030
• 6.3. Hospitals
  • 6.3.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.4. Imaging Centers
  • 6.4.1. Imaging centers market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.5. Ambulatory Surgical Centers and Other Healthcare Settings
  • 6.5.1. Ambulatory Surgical Centers and Other Healthcare Settings market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Market Participant Categorization
  • 7.2.1. GE Healthcare
    • 7.2.1.1. Company overview
    • 7.2.1.2. Financial performance
    • 7.2.1.3. Product benchmarking
    • 7.2.1.4. Strategic initiatives
  • 7.2.2. Koninklijke Philips N.V.
    • 7.2.2.1. Company overview
    • 7.2.2.2. Financial performance
    • 7.2.2.3. Product benchmarking
    • 7.2.2.4. Strategic initiatives
  • 7.2.3. Siemens Healthcare GmbH
    • 7.2.3.1. Company overview
    • 7.2.3.2. Financial performance
    • 7.2.3.3. Product benchmarking
    • 7.2.3.4. Strategic initiatives
  • 7.2.4. Hitachi, Ltd.
    • 7.2.4.1. Company overview
    • 7.2.4.2. Financial performance
    • 7.2.4.3. Product benchmarking
    • 7.2.4.4. Strategic initiatives
  • 7.2.5. Canon, Inc.
    • 7.2.5.1. Company overview
    • 7.2.5.2. Financial performance
    • 7.2.5.3. Product benchmarking
    • 7.2.5.4. Strategic initiatives
  • 7.2.6. Shenzhen Anke Hi-Tech Co., Ltd.
    • 7.2.6.1. Company overview
    • 7.2.6.2. Financial performance
    • 7.2.6.3. Product benchmarking
    • 7.2.6.4. Strategic initiatives
  • 7.2.7. Time Medical Holding
    • 7.2.7.1. Company overview
    • 7.2.7.2. Financial performance
    • 7.2.7.3. Product benchmarking
    • 7.2.7.4. Strategic initiatives
  • 7.2.8. ASG Superconductors SpA
    • 7.2.8.1. Company overview
    • 7.2.8.2. Financial performance
    • 7.2.8.3. Product benchmarking
    • 7.2.8.4. Strategic initiatives
  • 7.2.9. Neusoft Corporation
    • 7.2.9.1. Company overview
    • 7.2.9.2. Financial performance
    • 7.2.9.3. Product benchmarking
    • 7.2.9.4. Strategic initiatives
  • 7.2.10. Shimadzu Corporation
    • 7.2.10.1. Company overview
    • 7.2.10.2. Financial performance
    • 7.2.10.3. Product benchmarking
    • 7.2.10.4. Strategic initiatives
  • 7.2.11. ESAOTE SpA
    • 7.2.11.1. Company overview
    • 7.2.11.2. Financial performance
    • 7.2.11.3. Product benchmarking
    • 7.2.11.4. Strategic initiatives
  • 7.2.12. AllTech Medical Systems
    • 7.2.12.1. Company overview
    • 7.2.12.2. Financial performance
    • 7.2.12.3. Product benchmarking
    • 7.2.12.4. Strategic initiatives
  • 7.2.13. CentraCare
    • 7.2.13.1. Company overview
    • 7.2.13.2. Financial performance
    • 7.2.13.3. Product benchmarking
    • 7.2.13.4. Strategic initiatives
  • 7.2.14. Radiology Associates of Ocala
    • 7.2.14.1. Company overview
    • 7.2.14.2. Financial performance
    • 7.2.14.3. Product benchmarking
    • 7.2.14.4. Strategic initiatives
  • 7.2.15. Hunt Regional Healthcare
    • 7.2.15.1. Company overview
    • 7.2.15.2. Financial performance
    • 7.2.15.3. Product benchmarking
    • 7.2.15.4. Strategic initiatives
  • 7.2.16. Montgomery Radiology Associates
    • 7.2.16.1. Company overview
    • 7.2.16.2. Financial performance
    • 7.2.16.3. Product benchmarking
    • 7.2.16.4. Strategic initiatives